Shares of Replimune Group, Inc. (REPL) have gained 0.7% over the past four weeks to close the last trading session at $7.76, but there could still be a solid upside left in the stock if short-term ...

Abstract: Bayesian inference provides a methodology for parameter estimation and uncertainty quantification in machine learning and deep learning methods. Variational inference and Markov Chain ...

With countless applications and a combination of approachability and power, Python is one of the most popular programming languages for beginners and experts alike. We’ve compiled a list of 10 online ...

This beginner-friendly tutorial shows how to create clear, interactive graphs in GlowScript VPython. You’ll learn the basics of setting up plots, graphing data in real time, and customizing axes and ...

Send a note to Doug Wintemute, Kara Coleman Fields and our other editors. We read every email. By submitting this form, you agree to allow us to collect, store, and potentially publish your provided ...

Community driven content discussing all aspects of software development from DevOps to design patterns. Ready to develop your first AWS Lambda function in Python? It really couldn’t be easier. The AWS ...

Thinking about learning Python? It’s a pretty popular language these days, and for good reason. It’s not super complicated, which is nice if you’re just starting out. We’ve put together a guide that ...

Replimune (NASDAQ:REPL) climbed more than 100% on Wednesday as Cantor Fitzgerald upgraded the cancer drug developer, citing a potential reversal of an FDA decision that rejected its lead drug ...

Recent discussions on X about Replimune Group Inc. (REPL) have been ignited by the U.S. FDA's rejection of the company's lead drug, RP1, for melanoma treatment in combination therapy. Many users are ...